Autopsy report · NCT00138125

Fulvestrant and/or Trastuzumab as First-Line Therapy in Treating Postmenopausal Women With Stage IV Breast Cancer

“Due to low accrual”

The sponsor’s own words in the registry.

Life of this trial

• Registered 4 months after it had already started.
• Ran for about 4 years 8 months before it stopped.
• 2 participants enrolled.
• Results were posted on the registry 3 years 2 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Translational Oncology Research International

Sponsor type

University, hospital or other

Conditions

Breast Cancer

Interventions

Faslodex; Herceptin

Participants

2

Sites

3

Countries

United States

Trials that died the same way

• Myocet Plus Endoxan for Older Patients With Breast Cancer
  “Due to poor accrual” (93% match in meaning)
• Staging Procedures to Diagnose Malignant Pleural Mesothelioma
  “due to low/slow accrual” (88% match in meaning)
• Bortezomib (Velcade) With Standard Chemotherapy for Relapsed or Refractory Follicular Lymphoma
  “Low accrual.” (83% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.